Exome sequencing delivers a comprehensive and highly accurate view of your genetic makeup offering a far greater diagnostic success rate than standard multigene panels or chromosomal microarray testing.
70% of genetic conditions appear during childhood, yet many families face years of uncertainty before receiving answers. On average:
Every day without a diagnosis means lost time—and missed opportunities for timely treatment. Early access to genetic insights can:
Leading medical organizations recommend exome sequencing as a first-line approach:
The American College of Medical Genetics and Genomics (ACMG) recommends exome or genome sequencing as a first-line test for individuals with developmental delays, intellectual disability, or congenital anomalies.
The National Society of Genetic Counselors, with endorsement from the American Epilepsy Society, advises exome or genome sequencing for all individuals with unexplained epilepsy.
Choosing Novagen Clinical Lab means choosing clarity, accuracy, and innovation:
Higher diagnostic yield compared to chromosomal microarray (CMA) testing
23% of patients receive diagnoses that traditional multigene panels would miss Streamlined testing for faster, more personalized care plans
Join healthcare organizations nationwide that are improving patient outcomes and efficiency with Novagen Clinical Lab advanced exome and genome testing solutions.